Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes.
Dulos J, Wijnands FP, van den Hurk-van Alebeek JA, van Vugt MJ, Rullmann JA, Schot JJ, de Groot MW, Wagenaars JL, van Ravestein-van Os R, Smets RL, Vink PM, Hofstra CL, Nelissen RL, van Eenennaam H. Dulos J, et al. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):515-25. Epub 2013 Apr 3. Clin Exp Rheumatol. 2013. PMID: 23558031
A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.
Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, Rooseboom M, Kreutzer H, Cavalcanti F, Boots AM, Nelissen RL. Mihara K, et al. Among authors: dulos j. Br J Pharmacol. 2008 May;154(1):153-64. doi: 10.1038/bjp.2008.53. Epub 2008 Feb 25. Br J Pharmacol. 2008. PMID: 18297096 Free PMC article.
Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.
Kaptein A, Oubrie A, de Zwart E, Hoogenboom N, de Wit J, van de Kar B, van Hoek M, Vogel G, de Kimpe V, Schultz-Fademrecht C, Borsboom J, van Zeeland M, Versteegh J, Kazemier B, de Roos J, Wijnands F, Dulos J, Jaeger M, Leandro-Garcia P, Barf T. Kaptein A, et al. Among authors: dulos j. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3823-7. doi: 10.1016/j.bmcl.2011.04.016. Epub 2011 Apr 16. Bioorg Med Chem Lett. 2011. PMID: 21565498
Therapeutic antibody targeting of CD97 in experimental arthritis: the role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2.
de Groot DM, Vogel G, Dulos J, Teeuwen L, Stebbins K, Hamann J, Owens BM, van Eenennaam H, Bos E, Boots AM. de Groot DM, et al. Among authors: dulos j. J Immunol. 2009 Sep 15;183(6):4127-34. doi: 10.4049/jimmunol.0901253. Epub 2009 Aug 28. J Immunol. 2009. PMID: 19717518 Free article.
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab.
Hutchins B, Starling GC, McCoy MA, Herzyk D, Poulet FM, Dulos J, Liu L, Kang SP, Fayadat-Dilman L, Hsieh M, Andrews CL, Ayanoglu G, Cullen C, Malefyt RW, Kastelein RA, Saux SL, Lee J, Li S, Malashock D, Sadekova S, Soder G, van Eenennaam H, Willingham A, Yu Y, Streuli M, Carven GJ, van Elsas A. Hutchins B, et al. Among authors: dulos j. Mol Cancer Ther. 2020 Jun;19(6):1298-1307. doi: 10.1158/1535-7163.MCT-19-0774. Epub 2020 Mar 30. Mol Cancer Ther. 2020. PMID: 32229606
18 results